Citation Impact
Citing Papers
Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry
2015 StandoutNobel
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Diagnosis, management, and treatment of hepatitis C†
2004
The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection
2003
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Impact of highly active antiretroviral therapy on the spectrum of liver disease in hcv-hiv coinfection
2004
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management
2007 Standout
Mechanisms of liver fibrosis
2005
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
2005 Standout
Enterohepatic cycling of bilirubin as a cause of ‘black’ pigment gallstones in adult life
2003
Course and outcome of hepatitis C
2002
Dynamics of Alanine Aminotransferase During Hepatitis C Virus Treatment
2003
Natural history of chronic hepatitis C
2002
Immunology of hepatitis B virus and hepatitis C virus infection
2005 Standout
Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT
2004
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient
2016 Standout
Global epidemiology of hepatitis C virus infection
2005 Standout
The NAFLD fibrosis score
2007 Standout
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Simultaneous liquid chromatographic assessment of thiamine, thiamine monophosphate and thiamine diphosphate in human erythrocytes: a study on alcoholics
2003
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient
2016 Standout
Clinical management of HCV carriers with normal aminotransferase levels
2003
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
2012 Standout
Viral Dynamics and Response Differences in Hcv–Infected African American and White Patients Treated With Ifn and Ribavirin
2003
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan
2008
Role of Liver Biopsy in the Evaluation of Hepatitis C Virus Infection in HIV Coinfection
2005
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
2004
American Gastroenterological Association Technical Review on the Management of Hepatitis C
2006
The history of the “natural history” of hepatitis C (1968–2009)
2009
Treatment of hepatitis C
2005
Anti‐HCV therapies in chimeric scid‐Alb/uPA mice parallel outcomes in human clinical application†
2006
Fibrosis and disease progression in hepatitis C
2002
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
FIB-4
2007 Standout
The utility of radiological imaging in nonalcoholic fatty liver disease
2002 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels
2006
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
2006 Standout
The role of liver biopsy in chronic hepatitis C
2002
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
2006 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
A 24‐week course of high‐dose interferon‐α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near‐normal alanine aminotransferase levels
2006
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study
2002
Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production
2005 StandoutNobel
Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer
2012 Standout
Replication of hepatitis C virus
2007 StandoutNobel
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
2016 Standout
Fibrosis and disease progression in hepatitis C
2002
Hepatitis C in the General Adult Population of Oslo: Prevalence and Clinical Spectrum
2003
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Enhancement of hepatitis C viral RNA abundance by precursor miR-122 molecules
2013 StandoutNobel
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
2005 StandoutNobel
Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis
2007
Antiviral Stilbene 1,2-Diamines Prevent Initiation of Hepatitis C Virus RNA Replication at the Outset of Infection
2011 StandoutNobel
Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection
2016
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
2006 Standout
Phenotypes of Interferon-α-Induced Thyroid Dysfunction among Patients Treated for Hepatitis C Are Associated with Pretreatment Serum TSH and Female Sex
2012
The role of liver biopsy in chronic hepatitis C
2002
Course and outcome of hepatitis C
2002
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
2007
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Kinetics of CD4+and CD8+Memory T-Cell Responses during Hepatitis C Virus Rechallenge of Previously Recovered Chimpanzees
2003 StandoutNobel
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
2005 StandoutScience
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Role of Nutrition in the Management of Hepatic Encephalopathy in End-Stage Liver Failure
2010
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?
2005
Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies
2003
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
Natural history of chronic hepatitis C
2002
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease
2006 StandoutNatureNobel
Works of Stéphane Lévy being referenced
Thiamine Deficiency in Hepatitis C Virus and Alcohol-Related Liver Diseases
2002
Daily or three times per week interferon α-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone
2002
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA
2001
Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C
2005
TREATMENT OF HEPATITIS C PATIENTS WITH NORMAL AMINOTRANSFERASES LEVELS
1999
Cirrhosis: A New, But Expected Cause of Biliary Sludge
1997
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C
2002